2,829 results on '"Paul, J. A."'
Search Results
2. Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma
3. Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL
4. An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML
5. Trafficking between clonally related peripheral T-helper cells and tissue-resident T-helper cells in chronic GVHD
6. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma
7. High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis
8. Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation
9. Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia
10. Tolerogenic anti–IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity
11. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells
12. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
13. How I treat steroid-refractory acute graft-versus-host disease
14. CD24Fc to DAMPen GVHD
15. Combined targeted modality in cHL: a risky bet?
16. UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice
17. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding
18. Balancing risk and benefit in early-stage classical Hodgkin lymphoma
19. AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses
20. Contrasting Features of T-Cell Expansion in Classical Hodgkin Lymphoma: Tumor Microenvironment Vs. Peripheral Blood and before Vs. during Anti-PD1 Treatment
21. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
22. Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis
23. An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease
24. Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation
25. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
26. Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature
27. Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease
28. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry
29. Epi(geneti)c makeover: boosting anti-PD-1 in HL
30. Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms
31. CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
32. Replication of associations between genetic polymorphisms and chronic graft-versus-host disease
33. A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia
34. Genetic risk factors for sclerotic graft-versus-host disease
35. Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma
36. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells
37. Decitabine enhances anti-CD33 monoclonal antibody BI 836858–mediated natural killer ADCC against AML blasts
38. Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice
39. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma
40. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation
41. Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease
42. Hematopoietic stem cell transplantation for infantile osteopetrosis
43. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment
44. Regulation of ribosomal RNA synthesis in T cells: requirement for GTP and Ebp1
45. The role of hematologists in a changing United States health care system
46. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study
47. Acetylation of C/EBPε is a prerequisite for terminal neutrophil differentiation
48. Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
49. Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
50. Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.